Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Bristol-Myers Squibb Company stock

Learn how to easily invest in Bristol-Myers Squibb Company stock.

Bristol-Myers Squibb Company is a drug manufacturers-general business based in the US. Bristol-Myers Squibb Company shares (BMY) are listed on the NYSE and all prices are listed in US Dollars. Bristol-Myers Squibb Company employs 32,200 staff and has a trailing 12-month revenue of around $46.7 billion.

How to buy Bristol-Myers Squibb Company stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – BMY. It's that simple.

Best for low fees

Finder Award

SoFi Invest


  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Promoted for easy user experience

Robinhood


  • Commission-free trading
  • Commission-free crypto
  • No minimum account balance

Promoted

tastyworks


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.

Bristol-Myers Squibb Company stock price (NYSE: BMY)

Use our graph to track the performance of BMY stocks over time.

Bristol-Myers Squibb Company shares at a glance

Information last updated 2023-01-25.
Latest market close$73.17
52-week range$60.97 - $80.80
50-day moving average $75.55
200-day moving average $74.52
Wall St. target price$82.19
PE ratio 23.5273
Dividend yield $2.16 (3.15%)
Earnings per share (TTM) $3.11

Buy Bristol-Myers Squibb Company stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Public.com
Stocks, ETFs, Cryptocurrency, Alternatives
$0
$0
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
$0
$0
N/A
Winner of Finder’s Best Overall Stock Broker award.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Bristol-Myers Squibb Company stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Bristol-Myers Squibb Company price performance over time

Historical closes compared with the close of $73.17 from 2023-01-25

1 week (2023-01-19) -0.79%
1 month (2022-12-23) 0.38%
3 months (2022-10-26) -1.72%
6 months (2022-07-26) -0.62%
1 year (2022-01-26) 17.56%
2 years (2021-01-26) 13.55%
3 years (2020-01-24) 14.04%
5 years (2018-01-26) 13.88%

Is Bristol-Myers Squibb Company stock undervalued or overvalued?

Valuing Bristol-Myers Squibb Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bristol-Myers Squibb Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Bristol-Myers Squibb Company's P/E ratio

Bristol-Myers Squibb Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 24x. In other words, Bristol-Myers Squibb Company shares trade at around 24x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Bristol-Myers Squibb Company's PEG ratio

Bristol-Myers Squibb Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.4369. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bristol-Myers Squibb Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Bristol-Myers Squibb Company's EBITDA

Bristol-Myers Squibb Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $20.7 billion.

The EBITDA is a measure of a Bristol-Myers Squibb Company's overall financial performance and is widely used to measure a its profitability.

Bristol-Myers Squibb Company financials

Revenue TTM $46.7 billion
Operating margin TTM 21.95%
Gross profit TTM $37 billion
Return on assets TTM 6.13%
Return on equity TTM 19.12%
Profit margin 14.29%
Book value $15.38
Market capitalisation $155.6 billion

TTM: trailing 12 months

Bristol-Myers Squibb Company's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Bristol-Myers Squibb Company.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Bristol-Myers Squibb Company's total ESG risk score

Total ESG risk: 29.16

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Bristol-Myers Squibb Company's overall score of 29.16 (as at 12/31/2018) is nothing to write home about – landing it in it in the 53rd percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Bristol-Myers Squibb Company is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Bristol-Myers Squibb Company's environmental score

Environmental score: 3.83/100

Bristol-Myers Squibb Company's environmental score of 3.83 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bristol-Myers Squibb Company is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Bristol-Myers Squibb Company's social score

Social score: 18.82/100

Bristol-Myers Squibb Company's social score of 18.82 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bristol-Myers Squibb Company is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Bristol-Myers Squibb Company's governance score

Governance score: 14.02/100

Bristol-Myers Squibb Company's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that Bristol-Myers Squibb Company is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Bristol-Myers Squibb Company's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Bristol-Myers Squibb Company scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Bristol-Myers Squibb Company has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Bristol-Myers Squibb Company was last rated for ESG on: 2019-01-01.

Total ESG score 29.16
Total ESG percentile 52.58
Environmental score 3.83
Environmental score percentile 4
Social score 18.82
Social score percentile 4
Governance score 14.02
Governance score percentile 4
Level of controversy 2

Bristol-Myers Squibb Company share dividends

16%

Dividend payout ratio: 15.8% of net profits

Recently Bristol-Myers Squibb Company has paid out, on average, around 15.8% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.15% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Bristol-Myers Squibb Company shareholders could enjoy a 3.15% return on their shares, in the form of dividend payments. In Bristol-Myers Squibb Company's case, that would currently equate to about $2.16 per share.

While Bristol-Myers Squibb Company's payout ratio might seem low, this can signify that Bristol-Myers Squibb Company is investing more in its future growth.

Bristol-Myers Squibb Company's most recent dividend payout was on 31 January 2023. The latest dividend was paid out to all shareholders who bought their shares by 4 January 2023 (the "ex-dividend date").

Have Bristol-Myers Squibb Company's shares ever split?

Bristol-Myers Squibb Company's shares were split on a 1000000:95 basis on 6 August 2001. So if you had owned 95 shares the day before before the split, the next day you'd have owned 1000000 shares. This wouldn't directly have changed the overall worth of your Bristol-Myers Squibb Company shares – just the quantity. However, indirectly, the new 100% lower share price could have impacted the market appetite for Bristol-Myers Squibb Company shares which in turn could have impacted Bristol-Myers Squibb Company's share price.

Bristol-Myers Squibb Company share price volatility

Over the last 12 months, Bristol-Myers Squibb Company's shares have ranged in value from as little as $60.9691 up to $80.8008. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Bristol-Myers Squibb Company's is 0.4255. This would suggest that Bristol-Myers Squibb Company's shares are less volatile than average (for this exchange).

Bristol-Myers Squibb Company overview

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company.

Frequently asked questions

What percentage of Bristol-Myers Squibb Company is owned by insiders or institutions?
Currently 0.067% of Bristol-Myers Squibb Company shares are held by insiders and 79.398% by institutions.
How many people work for Bristol-Myers Squibb Company?
Latest data suggests 32,200 work at Bristol-Myers Squibb Company.
When does the fiscal year end for Bristol-Myers Squibb Company?
Bristol-Myers Squibb Company's fiscal year ends in December.
Where is Bristol-Myers Squibb Company based?
Bristol-Myers Squibb Company's address is: 430 East 29th Street, New York, NY, United States, 10016
What is Bristol-Myers Squibb Company's ISIN number?
Bristol-Myers Squibb Company's international securities identification number is: US1101221083
What is Bristol-Myers Squibb Company's CUSIP number?
Bristol-Myers Squibb Company's Committee on Uniform Securities Identification Procedures number is: 110122108

More guides on Finder

Ask an Expert

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site